BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2022 5:55:20 AM | Browse: 398 | Download: 594
 |
Received |
|
2021-07-30 04:12 |
|
Peer-Review Started |
|
2021-07-30 04:15 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-25 08:37 |
|
Revised |
|
2021-11-07 01:56 |
|
Second Decision |
|
2022-01-05 03:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-01-06 18:50 |
|
Articles in Press |
|
2022-01-06 18:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-25 13:57 |
|
Publish the Manuscript Online |
|
2022-02-11 05:55 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Juan Wang, Yong-Sheng Gao, Kun Xu and Xiao-Dong Li |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiao-Dong Li, MD, PhD, Doctor, Doctor, Professor, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan 250117, Shandong Province, China. sylxd1306@163.com |
| Key Words |
Long-term remission; Refractory metastatic extranodal natural killer/T-cell lymphoma; Histone deacetylase; Programmed death-ligand 1 antibody; Radiotherapy; Case report |
| Core Tip |
Extranodal natural killer/T-cell lymphoma (ENKTL) is a subtype of non-Hodgkin lymphoma with poor outcomes because ENKTL cells express high levels of P-glycoprotein that mediate tumour multidrug resistance. Furthermore, the standard treatment modality for chemotherapy-resistant ENKTL remains debated. We have experienced a patient with refractory metastatic ENKTL who was resistant to conventional DDGP chemotherapy. Following systemic therapy with atezolizumab and chidamide in combination with local radiotherapy, the patient achieved sustained remission of approximately 10 mo with minor adverse effects. |
| Publish Date |
2022-02-11 05:55 |
| Citation |
Wang J, Gao YS, Xu K, Li XD. Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report. World J Clin Cases 2022; 10(5): 1609-1616 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i5/1609.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i5.1609 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
